quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 13, 2026

Can Strong iPhone and Mac Portfolio Help Apple Stock Recover in FY26?

View original at finance.yahoo.com
Can Strong iPhone and Mac Portfolio Help Apple Stock Recover in FY26? Apple AAPL shares have dropped 4.2% year to date (YTD), outperforming close peers such as HP HPQ and Microsoft MSFT but lagging Amazon AMZN…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Apple shares are overvalued, as suggested by a Value Score of F

    60% confidence

  • Samsung's shipments declined 6% year over year with 20% market share

    60% confidence

  • The Zacks Consensus Estimate for Apple's fiscal 2026 revenues is pegged at $461.68 billion, indicating 10.94% growth over fiscal 2025

    60% confidence

  • Lenovo led PC market with 26.5% market share, trailed by HP and Dell Technologies with 19.3% and 16.5%, respectively. Apple had a 10.6% market share

    60% confidence

  • Global smartphone shipments declined 6% year over year in the first quarter of 2026, with Apple leading with 21% market share and shipments growing 5% year over year, driven by strong iPhone 17 demand and improved performance in China

    60% confidence

  • The Zacks Consensus Estimate for Apple's fiscal 2026 earnings is $8.40 per share, indicating 12.6% growth from fiscal 2025

    60% confidence

  • Worldwide PC shipments totaled 62.8 million units in the first quarter of 2026, up 4% year over year

    60% confidence

Data points we hold from this source

HP Inc. · market share19.3 percent
HP Inc. · pe ratio6.37 ratio
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Can Strong iPhone and Mac Portfolio Help Apple Stock Recover in FY26? — Source | Via News | pt.VIA.NEWS